comprehensive -WSS

comprehensive

author：hotspot 2025-09-09 19:32:36 - browse：63531

There’s a specter haunting Wall Street.

It started in biotech, where companies making drugs for the obesity-related liver disease NASH saw their valuations crash on the assumption that GLP-1 weight loss treatments would cut them out of the market. Then the Ozempic panic came for dialysis firms, whose stocks fell about 20% in a single day on the news that Novo Nordisk’s medicine had delayed the progression of kidney disease in a study enrolling people with type 2 diabetes.

Now analysts from every sector are cranking out research notes on the disparate, dramatic, and often debatable implications of GLP-1 drugs’ growing popularity, said Jared Holz, a health care specialist at Mizuho Securities. Buy Bumble, sell McDonald’s. Short Pepsi, go long Louis Vuitton. Put your money in sectors that cater to a svelte and sated brand of consumer, and get out of the ones that rely on excess and compulsion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： The woman behind the Dana Farber

hotspot

WSS

Roche to buy Carmot Therapeutics, developer of obesity drugs

Roche to buy Carmot Therapeutics, developer of obesity drugs

FDA approves world's first CRISPR

R1 RCM gets $5.8 billion buyout offer from private equity firm

STAT readers on older presidents, polypills, Medicare, and more

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

hotspot

comprehensive

focus

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Medicare inequities exacerbate Puerto Rico’s health disparities

After affirmative action ruling, medical educators look to 'holistic review'

Chemotherapy shortages won’t get better under Biden’s latest plan

23andMe had bad news about my health. I wish a person had delivered it

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

At least 13 dead in Texas as scorching temps continue

Why palliative psychiatry is worth discussing

Novavax promises a turnaround & Lilly roils the obesity market

Chemotherapy shortages won’t get better under Biden’s latest plan

knowledge

AI models in health care face new federal disclosure requirements

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Medicare inequities exacerbate Puerto Rico’s health disparities

Patients' immediate access to test results puts radiologists in a bind

What causes an itch? Researchers may have solved the mystery

NIH study of ME/CFS points to clear biological hallmarks

hotspot

hotspot

Wikipedia

focus